Although α7nAChR agonists have not yet been investigated for eating behavior effects in humans, preliminary animal work supports this idea, finding peripheral effects such as improved insulin sensitivity (Wang et al., 2011; Xu et al., 2012) and reduced weight gain and metabolic changes in a model of diabetes (Marrero et al., 2010). Here, CHRNA7 is linked to diabetes mellitus.